Helius Medical Technologies, Inc. to Present at the Dawson James Small Cap Growth Conference
October 12 2021 - 7:05AM
Helius Medical Technologies, Inc. (Nasdaq:
HSDT) (“Helius” or the “Company”), a neurotech company focused on
neurological wellness, today announced that Dane C. Andreeff,
President and Chief Executive Officer, will present at the Dawson
James Small Cap Growth Conference as follows:
Date: |
Thursday, October 21, 2021 |
Time: |
11:00-11:20AM ET |
Webcast: |
https://wsw.com/webcast/dawson6/hsdt/2039430 |
Helius’ management team will be conducting 1x1 meetings during
the conference. To schedule a meeting, please visit Dawson James
Small Cap Growth Conference.
The presentation will be webcast live at the aforementioned
time, and archived for 30 days thereafter, via the Company’s
website at www.heliusmedical.com, under the Newsroom section.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on
neurological wellness. The Company’s purpose is to develop, license
and acquire unique and non-invasive platform technologies that
amplify the brain’s ability to heal itself. The Company’s first
commercial product is the Portable Neuromodulation Stimulator
(PoNS™). For more information, visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is an innovative
non-surgical device, inclusive of a controller and mouthpiece,
which delivers electrical stimulation to the surface of the tongue
to provide treatment of gait deficit. The PoNS device has been
authorized by the U.S. Food and Drug Administration (“FDA”) for use
in the United States as a short term treatment of gait deficit due
to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is
to be used as an adjunct to a supervised therapeutic exercise
program in patients 22 years of age and over by prescription only.
PoNS is authorized for sale in Canada for two indications: PoNS is
authorized as short term treatment (14 weeks) of chronic balance
deficit due to mild-to-moderate traumatic brain injury and is to be
used in conjunction with physical therapy. PoNS is authorized for
use as a short term treatment (14 weeks) of gait deficit due to
mild and moderate symptoms from Multiple Sclerosis (MS) and is to
be used in conjunction with physical therapy. The PoNS™ is an
investigational medical device in the Australia (“AUS”) and is
currently under premarket review by the AUS Therapeutic Goods
Administration.
Investor Relations Contact:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024